An International Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma

Trial Profile

An International Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma

Suspended
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2018

At a glance

  • Drugs Melphalan (Primary)
  • Indications Cholangiocarcinoma; Liver cancer
  • Focus Therapeutic Use
  • Sponsors Delcath Systems
  • Most Recent Events

    • 30 Jan 2018 Planned End Date changed from 1 Feb 2018 to 1 Apr 2018.
    • 30 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.
    • 30 Jan 2018 Status changed from recruiting to suspended due to limited enrollment
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top